## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.6% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($172.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251215T080700 | Neutral | Relevance: 100%
- Quest Diagnostics (DGX) has seen mixed performance compared to the healthcare sector and competitors. While it lagged the State Street Health Care Select Sector SPDR ETF (XLV) over short and medium terms, DGX outperformed over the past 52 weeks. The company reported strong Q3 2025 results, exceeding analyst expectations for revenue and EPS, and raised its fiscal 2025 guidance.

**2. Aaron Wealth Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251217T082317 | Somewhat-Bullish | Relevance: 98%
- Aaron Wealth Advisors LLC has initiated a new investment in Quest Diagnostics (DGX), acquiring 7,618 shares valued at approximately $1.45 million. This comes as institutional investors now hold about 88.06% of the stock, despite recent significant insider selling, including the CEO reducing his stake by over 31%. Quest Diagnostics reported strong Q3 earnings, exceeding analyst estimates, and announced a quarterly dividend, with analysts maintaining a "Moderate Buy" consensus rating for the company.

**3. Quest Diagnostics Stock: Is DGX Outperforming the Healthcare Sector?**
- Source: Palmetto Grain Brokerage | 20251215T160802 | Neutral | Relevance: 96%
- Quest Diagnostics Incorporated (DGX) has seen mixed performance, with short-term underperformance compared to the State Street Health Care Select Sector SPDR ETF (XLV) but outperformance over the past 52 weeks. Despite reporting strong Q3 2025 results and raising guidance, the stock dropped intraday. Analysts are moderately bullish, with a "Moderate Buy" rating and an average price target indicating an 8.9% upside.

**4. Nonalcoholic Steatohepatitis Diagnostics Market Is Going to Boom |• Exact Sciences Corporation • Genfit SA**
- Source: openPR.com | 20251215T080932 | Somewhat-Bullish | Relevance: 84%
- Worldwide Market Reports (WMR) projects substantial growth for the Nonalcoholic Steatohepatitis Diagnostics Market, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report identifies key players such as Exact Sciences Corporation and Genfit SA and segments the market by types and applications. It provides actionable intelligence and forecasts using extensive primary and secondary research.

**5. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Barchart.com | 20251216T124258 | Somewhat-Bullish | Relevance: 72%
- Bio-Techne Corporation (TECH), a mid-cap life sciences company, has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date and over the past 52 weeks, despite a recent three-month gain. The company's Q1 2026 revenue declined due to headwinds in cell therapy timing and biotech funding softness. Despite its recent struggles, analysts maintain a "Strong Buy" rating for TECH with a significant upside to its mean price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.3x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.0B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.3 |
| Current P/E | 18.2 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.1% to 1.6% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.65), momentum weakening. RSI neutral at 41. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.56% (CS: 40) | Neutral |
| RSI_14 | 41.3 | Neutral |
| MACD Histogram | -0.65 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 1.011x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $179.03
- **Stop Loss:** $172.45 (3.7% risk)
- **Target:** $185.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 164
- **Position Value:** $29,360.92
- **Portfolio %:** 29.36%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*